ADMS:NSD-Adamas Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 5.34

Change

+0.01 (+0.19)%

Market Cap

USD 0.23B

Volume

0.24M

Average Target Price

USD 12.25 (+129.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-0.62 (-2.28%)

USD10.46B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
APHA Aphria Inc

-0.22 (-1.59%)

USD4.17B 60.60 454.68
CRON Cronos Group Inc

-0.05 (-0.62%)

USD2.93B 37.00 N/A
PCRX Pacira BioSciences, Inc

-0.65 (-1.00%)

USD2.81B 19.21 44.17
TLRY Tilray, Inc

-0.36 (-2.14%)

USD2.73B N/A N/A
ORGO Organogenesis Holdings Inc

+0.08 (+0.38%)

USD2.62B 128.13 72.14
IRWD Ironwood Pharmaceuticals, Inc

-0.05 (-0.41%)

USD1.75B 16.45 12.68
SUPN Supernus Pharmaceuticals, Inc

-0.09 (-0.29%)

USD1.66B 13.26 7.74

ETFs Containing ADMS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.33% 71% C- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.33% 71% C- 74% C
Trailing 12 Months  
Capital Gain 62.31% 70% C- 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.31% 70% C- 53% F
Trailing 5 Years  
Capital Gain -71.64% 28% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.64% 28% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -9.07% 38% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.07% 38% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 59.89% 34% F 27% F
Risk Adjusted Return -15.14% 45% F 18% F
Market Capitalization 0.23B 41% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -4.57 53% F 67% D+
EV/EBITDA 0.11 100% A+ 96% A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -42.71% 36% F 19% F
Return on Assets -17.35% 42% F 21% F
Debt to Equity Ratio -252.74% 89% B+ 97% A+
Technical Ratios  
Short Ratio 4.93 41% F 20% F
Short Percent 5.86% 60% D- 35% F
Beta 2.67 5% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.